Study Group: Physicians (Germany)
Council Members in this Study Group: 1171
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Volker Hoffmann, MDPartner/Owner
Diagnostic Imaging Center
Volker Hoffmann, MD, is a Diagnostic and Interventional Radiologist and one of the three owners of Diagnostic Imaging Center, a large private imaging center....
- Peter Rieckmann, MD
Professor of Neurology and MS Research Chair
UNIVERSITY OF BRITISH COLUMBIAPeter Rieckmann, MD, FRCPC, is a Professor of Neurology and MS Research Chair at the University of British Columbia, Canada. He has established the Western Canadian MS Research and Training Center at UBC, Vancouver and is member of the EndMS steering committee (Canadian MS society). He has served as...
Hossein Ghofrani, MDPhysician
JUSTUS-LIEBIG-UNIVERSITAET GIESSENHossein Ardeschir (Ardi) Ghofrani, MD, is Lead physician of the Pulmonary Hypertension Centre at the University of Giessen Lung Center (UGLC), Germany. Prof. Ghofrani is a Reviewer for various high impact scientific journals including Lancet, AJRCCM, Circulation, and Circulation research amongst others....
GLG NewsSM Analyses by this Study Group's Leading Experts (?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Studies favor new Amgen drug for osteoporosis - will the patients like to inject denosumab?
April 14, 2008
Amgen Drug Helps Bones | online.wsj.com
Postmenopausal osteoporosis is a real problem for a huge number of the older aged patients, and the population is aging. In daily orthopaedic praxis, I see a lot of osteoporosis related fractures of the wrist, the hip, and the vertebral column. Just yesterday, I operated a pseudarthrosis in the femoral...
-
Analysis of CRx-191 in Psoriasis - Comments
November 12, 2007
CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis | www.pipelinereview.com
The combination of a topical steroid with an antidepressant seems to be intriguing. Antidepressant have shown some anti-pruritic activity in atopic dermatitis. The major disadvantage of the current investigational drug is the sue with occlussive dressings. That makes it impossible to use the drug for...
-
November 9, 2007
Collagen Matrix, Inc. Receives FDA 510(k) Clearance For SynOss(TM) Synthetic Mineral Bone Graft Material | www.medicalnewstoday.com
The presented bone substitute is comparable to 240 others in Germany. Only a few bone substitutes differ by bone induction like (DBM(R) Synthes) or (Grafton). Osteoconductive bone substitutes are very common. Only PerOssal(R) by aap, also osteoconductive, is selectively loadable ...
-
NSF (Nephrogenic Systemic Fibrosis) - Gadoxetic Acid (Primovist)
October 9, 2007
Volker Hoffmann, MD, Partner/Owner, Diagnostic Imaging Center
Study Finds NSF More Common Than Previously Reported | www.dimag.com
Nephrogenic systemic fibrosis is becoming a severe problem for radiologist and industry as it may prevent physicians from using gadolinium containing contrast agents fearing that they induce nephrogenic systemic fibrosis even in patients without known kidney disease. A stable contrast agent with almost...
-
September 13, 2007
Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer | www.pipelinereview.com
The phase 2 trial data presents results with a better outcome for superficial bladder cancer patients as those treated with standard procedures. A complete remission result after 2 years of 67% is dramatically better then adjuvant Chemoinstillation of immune therapy by BCG. The most important question...
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Physician - Department Chair
- Owner
- Director
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Oncologists in Germany | 160 |
| Oncologists (Germany, France, Italy) | 344 |
| Oncologists (EU) | 761 |
| Cardiologists (EU) | 830 |
| Neurologists (EU) | 561 |
| Neurologists | 1866 |
| Orthopedic Surgeons (EU) | 380 |